Overnight dexamethasone test to screen for primary aldosteronism in patients on blood pressure medicines
Tests an overnight dexamethasone dose to screen adults on blood pressure medicines for aldosteronism.
Plain-language title generated from the registry record
Registry title: Overnight Dexamethasone in Primary Aldosteronism Screening
Key facts
- Where
- Gdansk, PolandSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 75 with suspected or diagnosed high blood pressure and an adrenal gland lesion, who have a 1-mg dexamethasone test planned.
- Age
- 40 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Suspected or diagnosed high blood pressure, with an adrenal lesion that looks like an adrenocortical adenoma or hyperplasia on imaging.
- Earlier treatment
- People on glucocorticoids, non-steroidal anti-inflammatory drugs, hormone replacement therapy, hormonal contraceptives or licorice cannot join.
- Biomarker or test result
- Aldosterone and renin results must be available at the one-day clinic stay. A 1-mg dexamethasone test must be scheduled, for possible mild autonomous cortisol secretion (MACS).
Main reasons for not taking part
- Renin above 46.1 mIU/l before the dexamethasone test
- Aldosterone below 3 ng/dl before the dexamethasone test
- Signs of adrenal hormone deficiency or excess other than MACS
- Secondary high blood pressure other than due to primary aldosteronism, established or suspected
- Kidney function (eGFR) below 45 ml/min/1.73m2, active cancer, or severe heart or blood vessel disease
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT06740838, who can take part
Where in Poland
- Department of Endocrinology and Internal Medicine, University Clinical Center, Medical University of GdanskGdansk, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Gdansk
- Trial code
- NCT06740838
- Record updated
- 2 October 2025
- Original description
The goal of this observational study is to learn whether screening for primary aldosteronism can be improved among patients on chronic blood pressure-lowering medications by ordering intake of 1 mg of dexamethasone prior to hormonal examinations.Read full original descriptionShow less
Overnight Dexamethasone in Primary Aldosteronism Screening in Patients on Interfering Therapy (the ODEPRASC Study)
The goal of this observational study is to learn whether screening for primary aldosteronism can be improved among patients on chronic blood pressure-lowering medications by ordering intake of 1 mg of dexamethasone prior to hormonal examinations.
Primary aldosteronism is a condition, in which an adrenal gland steroid aldosterone is released in excessive amounts; it commonly causes hypertension but requires specific therapy different from usually prescribed in other forms of hypertension.
Dexamethasone is a synthetic steroid used for both therapeutic and diagnostic purposes. A single 1 mg dexamethasone dose taken at 11 p.m. in order to measure hormone concentrations the following morning (so called overnight 1-mg dexamethasone test) is a commonly applied test in the work-up of adrenal disorders.
The main question the project aims to answer is:
Can screening for primary aldosteronism be improved among patients receiving blood pressure-lowering medications with overnight 1-mg dexamethasone intake?
Participants will undergo changes in their chronic medication to be able to definitely rule out or confirm primary aldosteronism in blood hormonal examinations. These modifications and modifications are not part of the research project.
For this project participants will be asked to
* undergo the 1-mg dexamethasone test one to three times in order to compare hormonal concentrations before and after it, * collect urine for 24 hours to determine aldosterone in the urine sample after medications interfering in aldosterone release are temporarily withdrawn.
Inclusion: suspected or diagnosed HT,; age between 40 and 75,; available aldosterone and renin result at the time of one-day clinic stay,; scheduled 1-mg-DXM test (indicated for possible mild autonomous cortisol secretion, MACS),; presence of an adrenal lesion with radiologic features of adrenocortical adenoma/hyperplasia.
Exclusion: therapy with glucocorticoids, non-steroidal anti-inflammatory drugs, hormonal replacement therapy, hormonal contraceptive therapy, and/or licorice intake,; comorbidities including: poorly controlled and/or other than type 2 diabetes mellitus (T2DM), present and past alcohol abuse, obesity grade 3 (i.e. body mass index of at least 40 kg/m2), severe CV disease disqualifying a patient from chronic medication modification, active malignancy, decompensated autoimmune disease as well as an autoimmune disease associated with cardiovascular and/or renal complications, estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2, poor physical condition, lack and withdrawal of consent for participation; baseline (pre-DXM) hyperreninemia (renin exceeding the upper limit of normal at the study site, i.e. 46.1 mIU/l, assay manufacturer: Diasorin),; baseline (pre-DXM) Ald<3 ng/dl,; overt clinical and/or biochemical features of adrenal hormone deficiency or excess other than MACS (8 a.m. cortisolemia in the 50-140 nmol/l range in the 1-mg DXM test),; established or suspected secondary HT other than due to PA,.